Eribulin plus or minus trastuzumab for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have breast cancer that is unresectable or metastatic (not fully removable) and is HER2-positive on a lab tissue test.
- Your cancer has progressed on or soon after your most recent treatment (during treatment, after, or within 6 months after finishing adjuvant therapy).
- You have had fewer than 4 prior treatment lines for metastatic/recurrent disease (not counting hormone-free or other non-metastatic adjuvant care).
- Your heart pumping ability is adequate: ejection fraction is 50% or higher.
- Your blood counts, kidney function, and liver function are within allowed ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial is testing a drug called eribulin (given alone or with other drugs) for people with advanced HER2-negative breast cancer that has already been treated with an ADC (antibody-drug conjugate). The goal is to see if this new treatment can help control the cancer and potentially shrink tumors.
This trial tests a combination of three drugs for advanced breast cancer that is both hormone-receptor-positive and HER2-positive, and has stopped responding to a newer targeted therapy called T-DXd. The goal is to see if this new combo can shrink tumors or slow their growth.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a new combination of two drugs—trastuzumab, a standard targeted therapy, and retifanlimab, an immunotherapy—for people with early-stage HER2-positive breast cancer. The goal is to see if adding immunotherapy before surgery can improve outcomes.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.